Encode Bio is building a portfolio of technologies for drug discovery in such areas as protein kinase inhibitors and peptide therapeutics.
 

Proteio, Inc.* is developing proprietary in vivo metabolic labeling technology to measure the turnover of specific proteins as biomarkers of drug treatment effectiveness for diseases such as atherosclerosis.

SiDMAP, LLC⁺ provides metabolic profiling and phenotyping services and biomarker discovery services to pharmaceutical and biotech companies and other research organizations involved in drug R&D and in the study of disease.

* Co-founded by Convergent Investors, LLC
⁺ Company advised by Convergent Management, Inc.